Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.
about
Therapeutic Use of Native and Recombinant EnterovirusesReplication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical DataTrial Watch:: Oncolytic viruses for cancer therapyActivation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectorsOncolytic viruses: From bench to bedside with a focus on safety.Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancersCytolytic replication of echoviruses in colon cancer cell linesOncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.Curative one-shot systemic virotherapy in murine myeloma.Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit.Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.Intralesional immunotherapy for melanoma.Virotherapy in cancerOncolytic virus immunotherapy for melanoma.Intratumoral immunotherapy for melanoma.Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.Applications of coxsackievirus A21 in oncologyOncolytic viruses: a new class of immunotherapy drugs.Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines.Oncolytic virus therapy for cancer.Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5' RNA genome end methodology.Oncolytic immunotherapy: unlocking the potential of viruses to help target cancerEnhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation.Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment.Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.The Tanapoxvirus 142R Protein is a Serine-Threonine Kinase that Phosphorylates the Tumor Suppressor p53.Panorama from the oncolytic virotherapy summit.Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid.New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.Viral Vectors in Gene Therapy.Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
P2860
Q26767082-19B181D1-32B6-4FAF-9E0F-08103067387FQ26801501-46E74C83-93C2-4EBD-AC1F-F83DD5D61D0BQ27021951-5DB420F6-61EC-429A-894A-4455496269E7Q28744029-6494FB43-2FC4-4383-897E-BDE5C533D8ABQ34044071-F73BAC3C-3B09-4007-84B0-77EAB1815163Q34550450-92C21AA3-4245-4033-87B4-F30A6A37E65EQ34613146-411E1F85-C447-451F-B743-CE231498617AQ34707959-62127830-B618-4300-90A1-DEE3EE17FBBCQ35541517-E0D942F9-B418-48AF-BAFA-B188393EB7F2Q36099082-DD438B8C-BEB4-4C1D-8A9E-F6A1064DBF58Q36139716-1ACF1F12-9304-4D5E-8BE6-19EE3EAC7FD7Q37115384-464E449C-EA28-4ABA-AC6B-043A6F943DF5Q37120289-5FA51ED8-1568-445F-A37C-4A88998ED3BEQ37596657-ED25C7C4-A5CE-4501-A26F-A4F8A1FD86ADQ37629088-4C6DECFC-BC83-42ED-86BD-2421CA3F8400Q38168460-D5E52E19-DA0B-44E8-9570-3A4D38BE11C2Q38253646-E1528884-E4D7-45D3-8AD8-450454F1CED4Q38380394-B8EA485A-77B8-4BDE-A189-857E04C46318Q38518518-A3AD9D08-8304-4811-B688-F205FC817B53Q38534285-28FD1BA8-3FF6-4445-BC2E-3C5A7831431CQ38564325-F2B2018F-6363-4884-845D-7563D53F87C9Q38577450-8551E66C-EAC8-4AA4-AE2E-203F50DEDB90Q38646993-48597D84-94A6-4391-871E-C715E9844714Q38695916-0835175C-D18B-46BB-8D8F-D3944947D95BQ38924529-C35B9DCB-C1A7-4414-A633-76CFF13C4C70Q38972691-BA63F765-698B-4D8B-ABB7-4575FDAD5FBCQ39437344-4097454B-59CE-4271-8AEE-6B966C97D361Q39618095-DC92E221-D78E-4C72-9A97-80B94E7736B6Q39891152-3A416ADC-44B9-45B1-908C-23D89AAA3054Q40188505-AC7C0B16-53FC-4604-BF6D-38525818879AQ41684403-5F8586B5-5F47-4C4F-B9D2-7A0AFCE31BC2Q42271907-0F6AB687-982B-48F5-A2FB-11A353FEE9F6Q42934744-8CF0C7FA-A35F-4377-B28F-0AEA81999510Q44135421-762E07B8-C717-4A61-B98D-22733E131796Q50056861-E3BA9F43-42F5-42AB-A663-64E2DFF0F300Q55408780-372FD4F0-FDC4-4589-9D18-0A56E13B9377Q55510540-4FA24413-566C-474B-BA22-B915558CB06E
P2860
Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@ast
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@en
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@nl
type
label
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@ast
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@en
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@nl
prefLabel
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@ast
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@en
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@nl
P2093
P1476
Systemic therapy of malignant ...... terovirus, coxsackievirus a21.
@en
P2093
Darren R Shafren
E Susanne Johansson
Erin S Haley
Gough G Au
Leone Beagley
Nicole G Newcombe
Peter Hersey
Richard D Barry
Tam Nguyen
P356
10.1158/1078-0432.CCR-0690-3
P407
P433
P577
2004-01-01T00:00:00Z